IR
CRL icon

Invictus RG’s Charles River Laboratories CRL Stock Holding History

Invictus RG’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-3,375
Closed -$360K – 226
2018
Q1 		$360K Buy
+3,375
New +$364K 0.24% 103
2017
Q4 		– Sell
-201
Closed -$22K – 302
2017
Q3 		$22K Sell
201
-1,636
-89% -$168K 0.02% 428
2017
Q2 		$186K Sell
1,837
-2,301
-56% -$212K 0.14% 279
2017
Q1 		$372K Buy
+4,138
New +$351K 0.25% 138

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invictus RG's CRL Position: Q2 2018 in Review

Invictus RG sold out of Charles River Laboratories (CRL) in Q2 2018, closing a stake of 3,375 shares — an estimated $360K sold.

Invictus RG first reported a position in CRL in Q1 2017 and held it in 4 quarters. The position peaked at $372K in Q1 2017. 348 funds tracked by Wall St. Rank hold CRL as of Q2 2018.

  • Invictus RG reported no remaining Charles River Laboratories position as of Q2 2018 after selling out during the quarter.
  • Invictus RG sold 3,375 Charles River Laboratories shares in Q2 2018, an estimated $360K.
  • Invictus RG first reported a position in Charles River Laboratories in Q1 2017 and held it in 4 quarters.
  • Invictus RG's Charles River Laboratories position peaked at $372K in Q1 2017.
  • 348 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2018.

Based on Invictus RG's 13F filing for Q2 2018, filed 13 Aug 2018.